✦ LIBER ✦

BCR–ABL activates STAT3 via JAK and MEK pathways in human cells

✍ Scribed by Paul Coppo; Stéphane Flamant; Véronique De Mas; Peggy Jarrier; Martine Guillier; Marie-Laure Bonnet; Catherine Lacout; François Guilhot; William Vainchenker; Ali G. Turhan

Book ID: 108673829
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 316 KB
Volume: 134
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2006.06161.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

✍ Steelman, L S; Pohnert, S C; Shelton, J G; Franklin, R A; Bertrand, F E; McCubre 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 592 KB

MEK kinase 1 is essential for Bcr–Abl-in

MEK kinase 1 is essential for Bcr–Abl-induced STAT3 and self-renewal activity in embryonic stem cells

✍ Nakamura, Yukinori; Yujiri, Toshiaki; Nawata, Ryouhei; Tagami, Kozo; Tanizawa, Y 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 344 KB

Constitutive and specific activation of

Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells

✍ Coppo, Paul; Dusanter-Fourt, Isabelle; Millot, Gael; Nogueira, Maria Manuela; Du 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 348 KB

Interferon-γ enhances superoxide product

Interferon-γ enhances superoxide production in human mesangial cells via the JAK–STAT pathway

✍ Moriwaki, K; Kiyomoto, H; Hitomi, H; Ihara, G; Kaifu, K; Matsubara, K; Hara, T; 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 156 KB

Synergistic interactions between MEK1/2

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

✍ Yu, C; Dasmahapatra, G; Dent, P; Grant, S 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 249 KB

Role of RAF/MEK/ERK pathway, p-STAT-3 an

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

✍ Paola Ulivi; Chiara Arienti; Dino Amadori; Francesco Fabbri; Silvia Carloni; Ann 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

## Abstract Sorafenib is a multikinase inhibitor that has shown promising therapeutic results in different tumor histotypes, both as a single agent or in combination with other treatments. We analyzed the in vitro activity of sorafenib in pancreatic cancer, one of the most lethal and chemo‐radio‐re